Trial Profile
Long term prospective observational cohort study of the safety and efficacy of certolizumab pegol in the daily clinical practice of rheumatoid arthritis with emphasis on the lipid profile
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Sep 2019
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 30 Aug 2019 Results assessing the relationship between certolizumab concentrations, ADAs, and the effective TNF neutralising capacity in sera of rheumatoid arthritis patients, published in the Clinical and Experimental Rheumatology
- 15 Jul 2011 New trial record